『Navigating MedTech in LATAM: A Pure Global Deep Dive into Medical Device Classification Rules in Brazil, Mexico, and Colombia』のカバーアート

Navigating MedTech in LATAM: A Pure Global Deep Dive into Medical Device Classification Rules in Brazil, Mexico, and Colombia

Navigating MedTech in LATAM: A Pure Global Deep Dive into Medical Device Classification Rules in Brazil, Mexico, and Colombia

無料で聴く

ポッドキャストの詳細を見る

このコンテンツについて

 In this episode of LATAM MedTech Insights, we demystify the complex web of medical device classification rules across Latin America's key markets. While most countries use a risk-based system, the specific requirements of agencies like Brazil's ANVISA, Mexico's COFEPRIS, and Colombia's INVIMA present unique challenges that can derail market entry for unprepared companies. We explore how seemingly minor details in documentation, translation, and local procedural norms can lead to major delays. This episode provides essential insights for any MedTech company looking to expand into this dynamic but demanding region, moving beyond the regulations to discuss real-world examples and common pitfalls. For example, consider a European MedTech company with a CE-marked Class IIa device. They targeted Colombia, assuming a smooth registration process due to the similar classification system. However, they faced a six-month delay because their technical dossier, while compliant in the EU, lacked specific local declarations and formatting required by INVIMA. This small oversight cost them a critical sales season and highlighted the importance of localized expertise. Key questions answered in this episode: - Why isn't there a single classification system for all of Latin America? - What's the crucial difference between Brazil's `Cadastro` and `Registro` pathways? - How can a reference country approval from the FDA help in Mexico, and what is the most common mistake companies make in the process? - Why does Colombia's EU-like system still catch experienced European manufacturers by surprise? - What are the top three documentation details that lead to registration rejection in these key markets? - How do device grouping or family definitions differ between ANVISA, COFEPRIS, and INVIMA? At Pure Global, we specialize in turning these regulatory challenges into market opportunities. Our combination of local experts in over 30 markets and advanced AI-powered data tools ensures your path to registration is clear and efficient. Don't let regulatory details derail your LATAM expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can accelerate your market access.
まだレビューはありません